Nigerian student, one other die after plasma donation in Canada

The recent confirmation by Health Canada of two fatal adverse reactions linked to plasma donation—including one involving a Nigerian national—has reignited critical questions about safety protocols and regulatory oversight in the global plasma collection industry. With one incident recorded in October 2025 and a second fatality confirmed on January 30, 2026, these deaths represent rare but serious complications that underscore vulnerabilities in an expanding sector increasingly dependent on international donor recruitment. For European investors monitoring opportunities in African healthcare and biotechnology sectors, these incidents carry significant implications. Nigeria and other sub-Saharan African nations have emerged as attractive markets for pharmaceutical and biotech companies seeking to expand plasma collection operations. The region's young, growing population and relatively lower healthcare costs have positioned it as a strategic hub for global plasma sourcing—a multi-billion-dollar industry supplying immunoglobulin therapies, clotting factors, and albumin products to hospitals worldwide. However, the Canadian incidents highlight systemic challenges that extend beyond individual cases. Plasma donation, while generally considered safe, carries documented risks including dehydration, electrolyte imbalances, and in rare cases, severe adverse reactions. The fact that Health Canada—one of the world's most stringent regulatory bodies—documented two fatalities within a four-month period suggests potential gaps in donor screening, informed